However, many models, including murine and human, in our hands showed surface expression of MHC-I and responsiveness to IFN-γ, whereby treatment of IFN-γ resulted in increase of MHC-I surface expression (Fig. 1C and SI Appendix, Fig. S1 A–C), suggesting that the cancer cells did not completely lose B2M or IFN-γ pathway genes. This evidence concerns the gene IFNG and cancer.